May 2026 in “International Journal of Dermatology” IL-17 and IL-23 inhibitors may cause hair loss.
April 2026 in “Canadian Medical Association Journal” This study reported that androgenetic alopecia in women becomes more prevalent with age, with risk factors including heredity and endocrine disorders, and differs clinically from male-pattern hair loss by causing diffuse hair thinning rather than loss at the temples or crown.
This scoping review reports that microneedling appears to be beneficial as an adjunctive therapy for cutaneous manifestations of autoimmune diseases like alopecia areata and vitiligo, improving outcomes when paired with other treatments, though evidence is limited and further research is needed.
April 2026 in “Research Square” This study found that COVID-19 infection disrupts spermatogenesis, alters testicular cell populations, and may impact male fertility by causing long-term changes in testicular function and reduced sperm quality, as observed even in patients who have recovered from the acute phase of the infection.
April 2026 in “Pediatric Dermatology” This review analyzes quality of life instruments for pediatric alopecia areata and reports inconsistencies in their coverage, suggesting the need for new tools to comprehensively assess all affected life aspects.
April 2026 in “Clinical and Experimental Dermatology” This study found that treating moderate-to-severe prurigo nodularis with dupilumab significantly improved itch severity, skin condition, and quality of life over 104 weeks, with a favorable safety profile, even in elderly and comorbid patients.
March 2026 in “Jurnal Biomedika dan Kesehatan” In this pilot study of Indonesians, the rs1998076 genetic variant was not significantly linked to androgenetic alopecia, though the GG genotype showed a non-significant trend toward higher odds, while clinical factors like age and hypertension were correlated with increased risk.
March 2026 in “Brazilian Journal of Animal and Environmental Research” This study observed that deslorelin acetate implants reduced sexual activity and improved coat quality in a German Spitz dog with alopecia X, suggesting its potential as a less invasive and reversible treatment for managing reproductive function and this dermatopathy.
March 2026 in “PubMed Central” This study reports that the prevalence of female pattern hair loss increases with age, affecting 12% of women by age 29, 25% by age 50, and 41% to 50% by age 70 and older, with risk factors including genetics and certain endocrinological conditions.
February 2026 in “Frontiers in Pediatrics” This case report describes a 7-year-old girl initially misdiagnosed with SMA syndrome, but later found to have a gastric trichobezoar via EGD, highlighting the diagnostic challenges in children with nonspecific symptoms.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” January 2026 in “International Journal of Dermatology” This study analyzed social media posts to assess pet toxicosis from topical minoxidil exposure, finding that many pet owners were unaware of its toxicity risks, particularly for cats, and highlighted a significant need for increased educational efforts to prevent such incidents.
January 2026 in “Advanced Healthcare Materials” This study introduces a new multiaxial bioreactor system that uniformly stretches tissue-engineered skin grafts and improves skin tissue maturation through enhanced cellular distribution and environmental monitoring.
December 2025 in “Jurnal Kesehatan Tambusai” This study examined the relationship between blood pressure and alopecia in Belitang, finding a significant association with higher blood pressure among those with alopecia and identifying an elevated risk in the Komering ethnic group, suggesting potential genetic factors.
December 2025 in “Asthma Allergy Immunology” This study found that among pediatric patients with inborn errors of immunity, severe COVID-19 was linked to chronic lung disease, hypogammaglobulinemia, and musculoskeletal abnormalities, with chronic pulmonary illness being a major risk factor, while long-term effects included fatigue, hair loss, and red eye.
December 2025 in “PubMed” In this study, researchers found that a propylene glycol-free and alcohol-reduced topical foam containing minoxidil and finasteride remained chemically, physically, and microbially stable for 180 days when stored properly at room temperature in light-resistant containers.
December 2025 in “International Journal of Dermatology” This systematic review reported that while combining low-dose oral minoxidil with Janus kinase inhibitors may enhance treatment outcomes in alopecia areata, the evidence remains weak due to limited sample sizes and potential publication bias, and more rigorous trials are necessary to assess efficacy and safety.
December 2025 in “Antibiotics” In this systematic review, researchers found that Tinea capitis in individuals aged 65 or older is frequently misdiagnosed, primarily affects women, and often presents with inflammatory symptoms; systemic antifungal therapy led to clinical cure in 91.2% of cases.
November 2025 in “IECCMEXICO” This review reports that 3D skin bioprinting has made significant progress towards clinical application, particularly in wound healing and disease modeling, but further work on vascularization and bioink standardization remains crucial.
November 2025 in “Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin” This study examined 16 sporadic trichoblastic tumors and found that although one showed malignant transformation, clinical follow-up revealed no residual or metastatic disease. RNA sequencing indicated a high tumor mutational burden and absence of a UV-related signature, helping to distinguish these tumors from similar growths.
November 2025 in “Molecular and Cellular Biomedical Sciences” This study found no significant association between the MMP-1 gene polymorphisms rs1799750 and androgenetic alopecia in the sample population.
November 2025 in “Journal of the European Academy of Dermatology and Venereology” In this study, single-cell RNA sequencing of hair follicle populations from hidradenitis suppurativa patients identified three endotypes, suggesting distinct epithelial-immune interactions that may guide stratified therapeutic approaches.
October 2025 in “International Journal of Dermatology” This review suggests weak associations between GLP-1 receptor agonists and increased reports of hair loss, particularly with semaglutide and tirzepatide, while cases of hair regrowth were also occasionally documented.
October 2025 in “Advanced Healthcare Materials” In a study on wound healing, researchers described injectable POEGMA‐DA hydrogels as a promising non-toxic alternative to traditional wound closure methods, showing effective tissue adhesion and enhanced regeneration of skin structures in a mouse model without significant inflammation.
October 2025 in “Environment International” This study reports that prenatal and prepubertal exposure to organochlorine compounds and perfluoroalkyl substances may affect pubertal development at age 12, with observed changes in development patterns in both girls and boys, highlighting the need for further research.
October 2025 in “The American Journal of Gastroenterology” In this case report, the researchers diagnosed a large trichobezoar in a 7-year-old girl with gastrointestinal symptoms and weight loss through endoscopy after inconclusive imaging, highlighting endoscopy's importance for accurate diagnosis and the need for surgical and behavioral intervention to prevent recurrence.
September 2025 in “JAAD reviews.” In this systematic review and meta-analysis, researchers evaluated the link between alopecia areata and adverse pregnancy outcomes, motivated by the condition's association with other autoimmune diseases that increase pregnancy risks. Results are not provided in the abstract.
September 2025 in “Journal of the American Academy of Dermatology” Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.
This study found that fibroblasts from Emery-Dreifuss muscular dystrophy patients with certain genetic mutations overexpress markers of fibrosis, and gene correction techniques reduced fibrogenic molecule expression in cell models, suggesting potential therapeutic applications.